Many preclinical and clinical studies have shown that anti-PD-1 therapy often leads to congenital and acquired drug resistance (85), leading to tumor recurrence and treatment failure in patients with patients with HCC (Figure 3). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.